Beam Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA



Growjo Ranking



Estimated Revenue & Valuation

  • Beam Therapeutics's estimated annual revenue is currently $67.7M per year.(i)
  • Beam Therapeutics received $135.0M in venture funding in March 2019.
  • Beam Therapeutics's estimated revenue per employee is $155,000
  • Beam Therapeutics's total funding is $689M.
  • Beam Therapeutics's current valuation is $4.6B. (January 2022}

Employee Data

  • Beam Therapeutics has 437 Employees.(i)
  • Beam Therapeutics grew their employee count by 93% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

Beam Therapeutics is developing precision genetic medicines for serious diseases. Co-founded by scientific pioneers known for advancing CRISPR gene editing, were the first company to pursue development of new therapies using CRISPR base editing technology. We aim to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. WHO WE ARE Beam is creating precision genetic medicines through base editing WHY WE DO IT Our dream is to provide life-long cures for patients suffering from serious diseases WHO WE ARE AND HOW WE WORK TOGETHER The Beam Team: A community of fearless innovators Rigorous and honest in our research Listening with open minds Committed to each other



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Beam Therapeutics News

2019-03-07 - Single-letter gene editing startup Beam Therapeutics raises $135M Series B round

The company launched last May, emerging from stealth mode with an $87 million Series A funding round led by ARCH and F-Prime. Beam’s technology is designed to edit the genome at the letter of the single letter – A (adenine), G (guanine), T (thymine) and C (cytosine) – rather than the more commo ...

2019-09-30 - Gene editing company Beam Therapeutics aims for $100M IPO

The company declined to comment because it is in a quiet period in connection with the filing. Beam’s last major financing was a $135 million Series B funding round that it raised in March. It launched in May of last year with an $87 million Series A round after operating in stealth mode for a ...

2020-02-06 - Beam Therapeutics raises $180 million in IPO

Beam Therapeutics (BEAM), a Cambridge, Mass., genome-editing startup, raised $180 million in an initial public offering Wednesday after increasing the number of shares it offered to investors by 48 percent. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET START ...

09/03/2019 - Beam Therapeutics Appoints Financial Industry Veteran, Terry-Ann Burrell, as Chief Financial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--. Beam Therapeutics, a biotechnology company developing precision genetic medicines through ...

09/08/2019 - Chutes & Ladders—Bausch Health's Salix loses McKenna to ...

LeSauteur comes out of the Human Health Therapeutics Research Center ... Cambridge, Massachusetts-based Beam Therapeutics has named ...

09/03/2019 - Growth of biopharma employment in Massachusetts

This year, Beam Therapeutics has been the largest beneficiary of venture capital, after raising $135m in its Series B financing round. However ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Beam Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-05-15$87.0MAF-Prime Capital PartnersArticle